<DOC>
	<DOCNO>NCT00512252</DOCNO>
	<brief_summary>This study phase I/II study determine safety efficacy AMD3100 combine mitoxantrone , etoposide , cytarabine patient relapse refractory AML . We hypothesize disrupt interaction AML blast marrow microenvironment AMD3100 may enhance cytotoxic effect chemotherapy .</brief_summary>
	<brief_title>AMD3100 Plus Mitoxantrone , Etoposide Cytarabine Acute Myeloid Leukemia</brief_title>
	<detailed_description>The interaction leukemic blast bone marrow microenvironment postulate important mediator chemoresistance AML . Although number receptor / ligand pair implicate , CXCR4 / SDF-1 axis function principal regulator home retention normal malignant hematopoietic cell marrow . AMD3100 bicyclam molecule reversibly block CXCR4 bind SDF-1 develop clinically mobilization agent hematopoietic stem cell transplantation . Preclinical data group demonstrate murine model , plerixafor disrupt interaction leukemic cell marrow microenvironment sensitize blast effect chemotherapy . Based data , initiated phase I/II study patient relapse refractory AML plerixafor administer prior salvage chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 . Acute myeloid leukemia diagnose WHO criteria one following : 1 . Primary refractory disease follow &gt; = 1 round induction chemotherapy 2 . First relapse high 2 . Age 18 70 year age 3 . Adequate organ function define Creatinine &lt; = 1.5 x institutional ULN ; AST , ALT , total bilirubin &lt; = 2 x ULN ; Left ventricular ejection fraction &gt; = 40 % MUGA scan 4 . Women childbearing potential sexually active male must willing able use effective contraception study 5 . Able provide sign informed consent prior registration study 1 . Acute promyelocytic leukemia ( AML ( 15 ; 17 ) ( q22 ; q11 ) variant ) 2 . Peripheral blood blast count &gt; 20 x 103 /mm3 3 . Active CNS involvement leukemia 4 . Previous treatment MEC regimen contain mitoxantrone etoposide 5 . Pregnant nursing 6 . Receiving investigational agent 7 . Colony stimulate factor filgrastim , pegfilgrastim sargramostim within 2 week study 8 . Less 2 week completion previous cytotoxic chemotherapy 9 . Severe concurrent illness would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Plerixafor</keyword>
	<keyword>CXCR4</keyword>
	<keyword>Chemosensitization</keyword>
</DOC>